Biotechnology company Zealand Pharma A/S (CPH:ZEAL) on Wednesday reported net loss of DKK272.3m, or DKK9.77 per diluted share, for the 12-month period, from 1 January 2017 to 31 December 2017.
This was a 77% decline over net loss of DKK153.9m, or DKK6.33 per diluted share, in 2016.
Revenues for the year were DKK139.8m, down by 40% as compared with DKK234.8m in 2016.
Royalty revenues for the year were DKK38.8m, up by 59% as compared with 2016, while milestone revenues were DKK101.0m, down by 52% as compared with 2016.
Reportedly, these full year results were in line with guidance.
(EUR1.00=DKK7.44)
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government